Local, systemic and immunologic safety comparison between xenogeneic equine umbilical cord mesenchymal stem cells, allogeneic canine adipose mesenchymal stem cells and placebo: a randomized controlled trial.
Authors: Punzón Eva, García-Castillo María, Rico Miguel A, Padilla Laura, Pradera Almudena
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Mesenchymal stem cells hold considerable promise for tissue regeneration in equine and canine medicine, yet safety data on cross-species (xenogeneic) applications remain limited in field conditions. Researchers administered equine umbilical cord-derived mesenchymal stem cells (EUC-MSCs), allogeneic canine adipose-derived cells (CAD-MSCs), or placebo via intra-articular injection to 24 working police dogs across three randomised groups, with both single and repeated dosing protocols, whilst monitoring local joint responses, systemic parameters, and humoral and cellular immune reactions. Despite robust antibody titre generation against both cell types, no adverse events were recorded in either treatment group, with joint pain assessments, orthopaedic examination findings, and blood work remaining unremarkable throughout the study period. These findings provide reassurance that xenogeneic equine stem cell therapy can be safely administered intra-articularly to dogs without triggering clinically significant inflammatory or immunological complications, even with repeated exposure. For equine practitioners, this xenogeneic safety profile may ultimately support development of off-the-shelf equine-derived cell therapies applicable across species, potentially offering cost-effective and readily available regenerative options, though further efficacy trials in horses with naturally occurring joint pathology remain essential before clinical adoption.
Read the full abstract on PubMed
Practical Takeaways
- •Equine umbilical cord stem cells can be safely used in canine patients without adverse reactions, suggesting potential cross-species therapeutic applications in veterinary medicine
- •Antibody formation against xenogeneic stem cells does not necessarily indicate clinical problems or contraindicate treatment in this short-term safety assessment
- •Both allogeneic and xenogeneic MSC products demonstrated equivalent safety profiles, though long-term immunologic effects and clinical efficacy remain to be determined
Key Findings
- •Xenogeneic equine umbilical cord mesenchymal stem cells (EUC-MSCs) showed no adverse events when administered intra-articularly in dogs following single and repeated doses
- •Both equine and canine MSCs generated antibody titres in recipient dogs despite safety profile
- •No local, systemic, or immunologic safety concerns detected with either allogeneic canine adipose mesenchymal stem cells (CAD-MSCs) or xenogeneic EUC-MSCs compared to placebo
- •Xenogeneic mesenchymal stem cell therapy appears safe for cross-species intra-articular use in this controlled study of 24 working dogs